sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
|
norepinephrine
|
monoamine oxidase inhibitors
|
EFFECT
|
Bupivacaine_ddi.xml
|
DDI-DrugBank.d153.s0
|
DDI-DrugBank.d153.s0.p7
|
Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.
|
rifampin
|
ZEBETA
|
MECHANISM
|
Bisoprolol_ddi.xml
|
DDI-DrugBank.d476.s4
|
DDI-DrugBank.d476.s4.p0
|
Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.
|
norfloxacin
|
anticoagulants
|
EFFECT
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s5
|
DDI-DrugBank.d217.s5.p3
|
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.
|
phenytoin
|
CANCIDAS
|
MECHANISM
|
Caspofungin_ddi.xml
|
DDI-DrugBank.d350.s12
|
DDI-DrugBank.d350.s12.p13
|
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
|
thyroid products
|
contraceptives
|
NONE
|
Glibenclamide_ddi.xml
|
DDI-DrugBank.d178.s4
|
DDI-DrugBank.d178.s4.p25
|
Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)
|
hydroflumethiazide
|
nonsteroidal anti-inflammatory agents
|
ADVISE
|
Hydroflumethiazide_ddi.xml
|
DDI-DrugBank.d17.s26
|
DDI-DrugBank.d17.s26.p0
|
Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
|
triazolam
|
fluvoxamine
|
MECHANISM
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s12
|
DDI-DrugBank.d76.s12.p14
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
phenylbutazone
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p36
|
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.
|
Cephalosporins
|
cefotetan
|
NONE
|
Menadione_ddi.xml
|
DDI-DrugBank.d139.s1
|
DDI-DrugBank.d139.s1.p3
|
Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
|
Aprepitant
|
itraconazole
|
ADVISE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s31
|
DDI-DrugBank.d382.s31.p1
|
Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
|
SPRYCEL
|
nefazodone
|
MECHANISM
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s1
|
DDI-DrugBank.d48.s1.p7
|
Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.
|
b-lactam antibiotics
|
cefditoren pivoxil
|
MECHANISM
|
Cefditoren_ddi.xml
|
DDI-DrugBank.d550.s4
|
DDI-DrugBank.d550.s4.p5
|
Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
|
felodipine
|
carbamazepine
|
MECHANISM
|
Felodipine_ddi.xml
|
DDI-DrugBank.d316.s14
|
DDI-DrugBank.d316.s14.p7
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
fenoprofen
|
indomethacin
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p892
|
Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.
|
beta-blocker
|
clonidine
|
ADVISE
|
Betaxolol_ddi.xml
|
DDI-DrugBank.d489.s4
|
DDI-DrugBank.d489.s4.p5
|
Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.
|
Vardenafil
|
tamsulosin
|
EFFECT
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s33
|
DDI-DrugBank.d198.s33.p0
|
Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.
|
Anticholinergic agents
|
anticholinergic medications
|
NONE
|
Ipratropium_ddi.xml
|
DDI-DrugBank.d51.s2
|
DDI-DrugBank.d51.s2.p1
|
Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.
|
TAXOL
|
cisplatin
|
MECHANISM
|
Paclitaxel_ddi.xml
|
DDI-DrugBank.d288.s1
|
DDI-DrugBank.d288.s1.p2
|
Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.
|
indomethacin
|
furosemide
|
EFFECT
|
Furosemide_ddi.xml
|
DDI-DrugBank.d231.s15
|
DDI-DrugBank.d231.s15.p0
|
No interactions have been observed between nizatidine and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin.
|
nizatidine
|
phenytoin
|
NONE
|
Nizatidine_ddi.xml
|
DDI-DrugBank.d475.s0
|
DDI-DrugBank.d475.s0.p4
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
fentanyl
|
hypnotics
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p26
|
Digitalis: Thyroid preparations may potentiate the toxic effects of digitalis.
|
Thyroid preparations
|
digitalis
|
EFFECT
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s17
|
DDI-DrugBank.d54.s17.p2
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
Probenecid
|
furosemide
|
MECHANISM
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p25
|
Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
|
diflunisal
|
phenprocoumon
|
EFFECT
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s0
|
DDI-DrugBank.d132.s0.p6
|
Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.
|
beta-blockers
|
Tiazac
|
EFFECT
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s1
|
DDI-DrugBank.d565.s1.p1
|
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
|
Benzthiazide
|
alcohol
|
INT
|
Benzthiazide_ddi.xml
|
DDI-DrugBank.d208.s0
|
DDI-DrugBank.d208.s0.p0
|
Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.
|
bupropion
|
levodopa
|
EFFECT
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s20
|
DDI-DrugBank.d5.s20.p7
|
Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.
|
neomycin sulfate
|
anticoagulants
|
EFFECT
|
Neomycin_ddi.xml
|
DDI-DrugBank.d330.s5
|
DDI-DrugBank.d330.s5.p1
|
There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.
|
trazodone hydrochloride
|
Desyrel
|
NONE
|
Buspirone_ddi.xml
|
DDI-DrugBank.d463.s1
|
DDI-DrugBank.d463.s1.p0
|
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.
|
Nalfon
|
salicylates
|
ADVISE
|
Fenoprofen_ddi.xml
|
DDI-DrugBank.d154.s2
|
DDI-DrugBank.d154.s2.p14
|
Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs 1500 M min in some patients.
|
Itraconazole
|
busulfan
|
MECHANISM
|
Busulfan_ddi.xml
|
DDI-DrugBank.d72.s0
|
DDI-DrugBank.d72.s0.p0
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
lovastatin
|
sulfonamides
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p480
|
Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.
|
felbamate
|
phenobarbital
|
NONE
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s28
|
DDI-DrugBank.d434.s28.p7
|
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
|
tobramycin
|
foscarnet
|
NONE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s3
|
DDI-DrugBank.d260.s3.p20
|
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
|
benzodiazepines
|
cyclosporine
|
INT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s10
|
DDI-DrugBank.d131.s10.p2
|
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
|
alprazolam
|
erythromycin
|
INT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s8
|
DDI-DrugBank.d131.s8.p66
|
Interaction of ketamine and halothane in rats.
|
ketamine
|
halothane
|
INT
|
1115367.xml
|
DDI-MedLine.d16.s0
|
DDI-MedLine.d16.s0.p0
|
Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.
|
Ketoconazole
|
vardenafil
|
MECHANISM
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s7
|
DDI-DrugBank.d198.s7.p0
|
Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids, estrogens, oral contraceptives containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.
|
androgens
|
estrogens
|
NONE
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s24
|
DDI-DrugBank.d54.s24.p8
|
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
|
Duloxetine
|
phenothiazines
|
ADVISE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s9
|
DDI-DrugBank.d548.s9.p6
|
The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
|
antipsychotic drug
|
trihexyphenidyl
|
EFFECT
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s0
|
DDI-DrugBank.d86.s0.p2
|
Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated.
|
Rifampin
|
amprenavir
|
MECHANISM
|
11158747.xml
|
DDI-MedLine.d3.s13
|
DDI-MedLine.d3.s13.p0
|
Loop Diuretics: Furosemide administered concurrently with captopril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.
|
captopril
|
captopril
|
NONE
|
Captopril_ddi.xml
|
DDI-DrugBank.d175.s22
|
DDI-DrugBank.d175.s22.p5
|
Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).
|
Diphenhydramine hydrochloride
|
tranquilizers
|
EFFECT
|
Diphenhydramine_ddi.xml
|
DDI-DrugBank.d296.s0
|
DDI-DrugBank.d296.s0.p4
|
If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.
|
isradipine
|
cimetidine
|
ADVISE
|
Isradipine_ddi.xml
|
DDI-DrugBank.d81.s8
|
DDI-DrugBank.d81.s8.p0
|
Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
|
Diuretic agents
|
lithium
|
MECHANISM
|
Chlorothiazide_ddi.xml
|
DDI-DrugBank.d46.s16
|
DDI-DrugBank.d46.s16.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Agenerase
|
Theo-Dur
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p817
|
Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.
|
Amphetamines
|
veratrum alkaloids
|
EFFECT
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s28
|
DDI-DrugBank.d236.s28.p2
|
The drug interaction between warfarin and rifampin is not well known.
|
warfarin
|
rifampin
|
INT
|
1115445.xml
|
DDI-MedLine.d116.s1
|
DDI-MedLine.d116.s1.p0
|
At least 3 weeks should elapse between discontinuation of dexfenfluramine and initiation of treatment with a MAO inhibitor.
|
dexfenfluramine
|
MAO inhibitor
|
ADVISE
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s3
|
DDI-DrugBank.d423.s3.p0
|
This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.
|
corticosteroids
|
azathioprine
|
NONE
|
7635041.xml
|
DDI-MedLine.d11.s4
|
DDI-MedLine.d11.s4.p6
|
Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).
|
VIDEX
|
ganciclovir
|
MECHANISM
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s6
|
DDI-DrugBank.d43.s6.p3
|
Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
|
ALPHAGAN P
|
sedatives
|
ADVISE
|
Brimonidine_ddi.xml
|
DDI-DrugBank.d138.s0
|
DDI-DrugBank.d138.s0.p4
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
monoamine oxidase inhibitors
|
fluoxetine
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p3
|
Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;
|
Amphetamines
|
sympathomimetic agents
|
EFFECT
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s3
|
DDI-DrugBank.d158.s3.p8
|
Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.
|
butorphanol
|
tranquilizers
|
EFFECT
|
Butorphanol_ddi.xml
|
DDI-DrugBank.d246.s0
|
DDI-DrugBank.d246.s0.p3
|
Narcotic analgesics may potentiate the hypotensive effects of clonidine.
|
Narcotic analgesics
|
clonidine
|
EFFECT
|
Clonidine_ddi.xml
|
DDI-DrugBank.d495.s3
|
DDI-DrugBank.d495.s3.p0
|
The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.
|
H2 blockers
|
SPRYCEL
|
ADVISE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s13
|
DDI-DrugBank.d48.s13.p4
|
Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.
|
5-fluorouracil
|
leucovorin
|
MECHANISM
|
Capecitabine_ddi.xml
|
DDI-DrugBank.d88.s5
|
DDI-DrugBank.d88.s5.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
anesthetics
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p24
|
Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.
|
fluvoxamine
|
N-desmethyldiazepam
|
MECHANISM
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s20
|
DDI-DrugBank.d76.s20.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
dextran
|
phenylbutazone
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p687
|
Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
|
levothyroxine sodium
|
aluminum hydoxide
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s2
|
DDI-DrugBank.d411.s2.p7
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
diltiazem
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p7
|
Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.
|
phenytoin
|
fludrocortisone acetate
|
MECHANISM
|
Fludrocortisone_ddi.xml
|
DDI-DrugBank.d526.s17
|
DDI-DrugBank.d526.s17.p4
|
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.
|
sertraline
|
paroxetine
|
NONE
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s16
|
DDI-DrugBank.d238.s16.p12
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
phenytoin
|
theophylline
|
EFFECT
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p10
|
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
|
Mefloquine
|
antihistamines
|
EFFECT
|
Mefloquine_ddi.xml
|
DDI-DrugBank.d220.s9
|
DDI-DrugBank.d220.s9.p3
|
Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
|
aspirin
|
magnesium salicylate
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s1
|
DDI-DrugBank.d521.s1.p19
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
bromelains
|
fenoprofen
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p369
|
An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels.
|
perchlorate
|
pertechnetate
|
MECHANISM
|
163470.xml
|
DDI-MedLine.d134.s2
|
DDI-MedLine.d134.s2.p0
|
Antacids containing magnesium, aluminum, or calcium;
|
magnesium
|
calcium
|
NONE
|
Nalidixic Acid_ddi.xml
|
DDI-DrugBank.d427.s8
|
DDI-DrugBank.d427.s8.p4
|
Therefore, patients on propranolol should be observed when COLESTID Tablets are either added or deleted from a therapeutic regimen.
|
propranolol
|
COLESTID
|
ADVISE
|
Colestipol_ddi.xml
|
DDI-DrugBank.d345.s9
|
DDI-DrugBank.d345.s9.p0
|
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
|
Barbiturates
|
theophylline
|
EFFECT
|
Hexobarbital_ddi.xml
|
DDI-DrugBank.d457.s0
|
DDI-DrugBank.d457.s0.p3
|
Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
|
Antacids
|
digoxin
|
MECHANISM
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s6
|
DDI-DrugBank.d450.s6.p5
|
In addition, most macrolides are contraindicated in patients receiving terfenadine therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.
|
macrolides
|
terfenadine
|
ADVISE
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s11
|
DDI-DrugBank.d522.s11.p0
|
Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.
|
zopiclone
|
rifampicin
|
MECHANISM
|
Eszopiclone_ddi.xml
|
DDI-DrugBank.d216.s10
|
DDI-DrugBank.d216.s10.p2
|
Heparin Sodium Injection should not be mixed with doxorubicin, droperidol, ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with heparin and a precipitate may form.
|
doxorubicin
|
ciprofloxacin
|
NONE
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s7
|
DDI-DrugBank.d488.s7.p6
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
levothyroxine sodium
|
perphenazine
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p12
|
Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.
|
ephedrine
|
sympathomimetic bronchodilators
|
EFFECT
|
Dyphylline_ddi.xml
|
DDI-DrugBank.d4.s0
|
DDI-DrugBank.d4.s0.p5
|
Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
|
fluconazole
|
cisapride
|
MECHANISM
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s7
|
DDI-DrugBank.d237.s7.p7
|
The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.
|
norfloxacin
|
glyburide
|
EFFECT
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s7
|
DDI-DrugBank.d217.s7.p3
|
Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.
|
lamivudine
|
zalcitabine
|
EFFECT
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s3
|
DDI-DrugBank.d263.s3.p2
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
diltiazem
|
ketoconazole
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p185
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
itraconazole
|
methadone
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p738
|
Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.
|
probenecid
|
cefdinir
|
MECHANISM
|
Cefdinir_ddi.xml
|
DDI-DrugBank.d420.s4
|
DDI-DrugBank.d420.s4.p7
|
SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.
|
SUSTIVA
|
itraconazole
|
MECHANISM
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s79
|
DDI-DrugBank.d531.s79.p0
|
Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine.
|
Ethopropazine
|
chlorpromazine
|
MECHANISM
|
Ethopropazine_ddi.xml
|
DDI-DrugBank.d240.s2
|
DDI-DrugBank.d240.s2.p0
|
Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;
|
Amprenavir
|
combination hormonal contraceptives
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s32
|
DDI-DrugBank.d485.s32.p8
|
Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3.
|
ketoconazole
|
erlotinib
|
MECHANISM
|
Erlotinib_ddi.xml
|
DDI-DrugBank.d456.s0
|
DDI-DrugBank.d456.s0.p0
|
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
|
erythromycin
|
lovastatin
|
INT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s8
|
DDI-DrugBank.d397.s8.p8
|
(Thiazide drugs may increase the responsiveness to tubocurarine.)
|
Thiazide drugs
|
tubocurarine
|
EFFECT
|
Hydroflumethiazide_ddi.xml
|
DDI-DrugBank.d17.s31
|
DDI-DrugBank.d17.s31.p0
|
Lithium: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.
|
Lithium
|
Ibuprofen
|
NONE
|
Ibuprofen_ddi.xml
|
DDI-DrugBank.d415.s12
|
DDI-DrugBank.d415.s12.p0
|
If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.
|
CEFOTAN
|
aminoglycoside
|
EFFECT
|
Cefotetan_ddi.xml
|
DDI-DrugBank.d483.s1
|
DDI-DrugBank.d483.s1.p0
|
ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
|
ZEBETA
|
myocardial depressants
|
ADVISE
|
Bisoprolol_ddi.xml
|
DDI-DrugBank.d476.s3
|
DDI-DrugBank.d476.s3.p0
|
DIGOXIN: Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.
|
digoxin
|
digoxin
|
NONE
|
Cerivastatin_ddi.xml
|
DDI-DrugBank.d141.s7
|
DDI-DrugBank.d141.s7.p3
|
Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.
|
magnesium
|
magnesium
|
NONE
|
7786695.xml
|
DDI-MedLine.d103.s1
|
DDI-MedLine.d103.s1.p11
|
Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions.
|
calcium-channel-blocking agents
|
diuretics
|
NONE
|
Benazepril_ddi.xml
|
DDI-DrugBank.d561.s11
|
DDI-DrugBank.d561.s11.p9
|
Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.
|
valdecoxib
|
ketoconazole
|
MECHANISM
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s28
|
DDI-DrugBank.d328.s28.p0
|
Aspirin: CELEBREX can be used with low dose aspirin.
|
Aspirin
|
CELEBREX
|
NONE
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s13
|
DDI-DrugBank.d172.s13.p0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.